Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV003019638 | SCV003321492 | uncertain significance | not provided | 2023-05-30 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. ClinVar contains an entry for this variant (Variation ID: 2102687). This variant has not been reported in the literature in individuals affected with GABRA2-related conditions. This variant is present in population databases (no rsID available, gnomAD 0.01%). This sequence change replaces arginine, which is basic and polar, with tryptophan, which is neutral and slightly polar, at codon 56 of the GABRA2 protein (p.Arg56Trp). |
Fulgent Genetics, |
RCV005034585 | SCV005665288 | uncertain significance | Alcohol dependence; Developmental and epileptic encephalopathy, 78 | 2024-05-31 | criteria provided, single submitter | clinical testing | |
Pediatric Neurology, |
RCV004698358 | SCV005199835 | likely pathogenic | Developmental and epileptic encephalopathy, 78 | no assertion criteria provided | clinical testing | This variant has been reported once in ClinVar (Variant ID: 2102687) and is considered to be of uncertain significance. However, the frequency of this variant is less than 0.0005 in all normal population databases, and it is a mutation in a gene with a mis_Z score greater than or equal to 3.09 in the GnomAD database. Moreover, statistical methods predict that the variant has an impact on the gene product. |